[go: up one dir, main page]

SG10201912530XA - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
SG10201912530XA
SG10201912530XA SG10201912530XA SG10201912530XA SG10201912530XA SG 10201912530X A SG10201912530X A SG 10201912530XA SG 10201912530X A SG10201912530X A SG 10201912530XA SG 10201912530X A SG10201912530X A SG 10201912530XA SG 10201912530X A SG10201912530X A SG 10201912530XA
Authority
SG
Singapore
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
SG10201912530XA
Inventor
Joanna Koziara
Diana Sperger
Original Assignee
Gilead Sciences Inc
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Janssen Sciences Ireland Uc filed Critical Gilead Sciences Inc
Publication of SG10201912530XA publication Critical patent/SG10201912530XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201912530XA 2015-06-30 2016-06-28 Pharmaceutical formulations SG10201912530XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562187102P 2015-06-30 2015-06-30
US201662296524P 2016-02-17 2016-02-17

Publications (1)

Publication Number Publication Date
SG10201912530XA true SG10201912530XA (en) 2020-02-27

Family

ID=56413867

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201912530XA SG10201912530XA (en) 2015-06-30 2016-06-28 Pharmaceutical formulations

Country Status (16)

Country Link
US (1) US20170027967A1 (en)
EP (1) EP3316869A1 (en)
JP (2) JP2018519325A (en)
KR (2) KR20200037880A (en)
CN (1) CN107921003A (en)
AU (1) AU2016285916B9 (en)
BR (1) BR112017028140A2 (en)
CA (1) CA2921336A1 (en)
EA (1) EA201792591A1 (en)
HK (2) HK1252156A1 (en)
IL (1) IL256491A (en)
MA (1) MA42303A (en)
MX (1) MX2017016802A (en)
NZ (1) NZ738524A (en)
SG (1) SG10201912530XA (en)
WO (1) WO2017004012A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344879B (en) 2012-12-21 2017-01-11 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use.
LT3236972T (en) 2014-12-26 2021-11-10 Emory University ANTIVIRAL N4-HYDROXICITIDINE DERIVATIVES
KR102606625B1 (en) 2015-11-09 2023-11-27 길리애드 사이언시즈, 인코포레이티드 Therapeutic Compositions for Treatment of Human Immunodeficiency Virus
WO2018064654A1 (en) * 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
TWI714820B (en) * 2017-01-31 2021-01-01 美商基利科學股份有限公司 Crystalline forms of tenofovir alafenamide
LT3706762T (en) 2017-12-07 2024-12-27 Emory University N4-HYDROXYCYTIDINE AND ITS DERIVATIVES AND RELATED ANTIVIRAL USES
SG11202009199YA (en) * 2018-03-25 2020-10-29 Biohaven Pharm Holding Co Ltd Rimegepant for cgrp related disorders
KR102281373B1 (en) 2018-04-26 2021-07-22 주식회사 엘지에너지솔루션 Cathode for solid electrolyte battery and solid electrolyte battery including the same
KR102016952B1 (en) * 2019-04-19 2019-09-02 유니셀랩 주식회사 The antiviral agent comprising a novel crystalline form and the manufacturing method thereof
CN114126655A (en) * 2019-07-03 2022-03-01 爱尔兰詹森科学公司 Methods of treating HIV in pediatric patients with rilpivirine
WO2021015818A1 (en) * 2019-07-19 2021-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv pre-exposure prophylaxis
CN117338733B (en) * 2023-10-12 2024-05-28 杭州和泽坤元药业有限公司 Tenofovir disoproxil fumarate tablets and preparation process thereof
CN119174735A (en) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 Compound tablet containing rilpivirine and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201691695A1 (en) * 2010-11-19 2017-11-30 Джилид Сайэнс, Инк. THERAPEUTIC COMPOSITIONS CONTAINING RILPIVIRIN HCL AND TENOFOVIRA DYSOPROXYL FUMARATE
BR112014018918A8 (en) * 2012-02-03 2017-07-11 Gilead Sciences Inc COMBINATION THERAPY COMPRISING TENOFOVIR ALAFENAMIDE HEMIFUMARATE AND COBICISTAT FOR USE IN THE TREATMENT OF VIRAL INFECTIONS
US20160184332A1 (en) * 2013-08-14 2016-06-30 Ratiopharm Gmbh Medicament comprising a pharmaceutical combination of drugs

Also Published As

Publication number Publication date
KR20180048584A (en) 2018-05-10
NZ738524A (en) 2019-02-22
HK1254343A1 (en) 2019-07-19
KR20200037880A (en) 2020-04-09
EP3316869A1 (en) 2018-05-09
US20170027967A1 (en) 2017-02-02
EA201792591A1 (en) 2018-06-29
JP2019116514A (en) 2019-07-18
AU2016285916B9 (en) 2019-04-04
AU2016285916B2 (en) 2019-03-07
AU2016285916A1 (en) 2018-01-18
WO2017004012A1 (en) 2017-01-05
MX2017016802A (en) 2018-09-06
JP2018519325A (en) 2018-07-19
MA42303A (en) 2018-05-09
CN107921003A (en) 2018-04-17
HK1252156A1 (en) 2019-05-17
BR112017028140A2 (en) 2018-08-28
IL256491A (en) 2018-02-28
CA2921336A1 (en) 2016-12-30

Similar Documents

Publication Publication Date Title
IL246978A0 (en) Novel pharmaceutical formulations
SI4070788T1 (en) Pharmaceutical formulations
ZA201903101B (en) Pharmaceutical formulations
IL256491A (en) Pharmaceutical formulations
GB201608323D0 (en) Pharmaceutical compositions
PT3426294T (en) Pharmaceutical formulation
IL253570B (en) Pharmaceutical formulation
IL266537A (en) Pharmaceutical formulation
IL262745A (en) Improved drug formulations
IL253177B (en) Pharmaceutical formulation
GB201521462D0 (en) Pharmaceutical composition
ZA201707094B (en) Pharmaceutical formulations
ZA201807851B (en) Pharmaceutical formulation
IL263040A (en) Pharmaceutical composition comprising eteplirsen
GB201515310D0 (en) Pharmaceutical composition
GB201506755D0 (en) Novel pharmaceutical formulation
IL255510A (en) Pharmaceutical compositions
IL271908A (en) Hypercompressed pharmaceutical formulations
GB201520862D0 (en) Pharmaceutical composition
GB201511246D0 (en) Pharmaceutical formulation
GB201417589D0 (en) Pharmaceutical Formulations
PL3424500T3 (en) Pharmaceutical composition comprising famitinib
GB201610440D0 (en) Pharmaceutical formulations
PT3319596T (en) Pharmaceutical compositions
GB201521456D0 (en) Pharmaceutical composition